JP2024513494A5 - - Google Patents
Info
- Publication number
- JP2024513494A5 JP2024513494A5 JP2023561863A JP2023561863A JP2024513494A5 JP 2024513494 A5 JP2024513494 A5 JP 2024513494A5 JP 2023561863 A JP2023561863 A JP 2023561863A JP 2023561863 A JP2023561863 A JP 2023561863A JP 2024513494 A5 JP2024513494 A5 JP 2024513494A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cancer
- alkoxy
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163172643P | 2021-04-08 | 2021-04-08 | |
| US63/172,643 | 2021-04-08 | ||
| US202163253029P | 2021-10-06 | 2021-10-06 | |
| US63/253,029 | 2021-10-06 | ||
| PCT/US2022/023388 WO2022216645A1 (en) | 2021-04-08 | 2022-04-05 | Combination therapies using prmt5 inhibitors for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024513494A JP2024513494A (ja) | 2024-03-25 |
| JP2024513494A5 true JP2024513494A5 (enExample) | 2025-04-14 |
Family
ID=81748438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023561863A Pending JP2024513494A (ja) | 2021-04-08 | 2022-04-05 | がんの治療のためのｐｒｍｔ５阻害剤を使用する併用療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12171765B2 (enExample) |
| EP (1) | EP4319753A1 (enExample) |
| JP (1) | JP2024513494A (enExample) |
| KR (1) | KR20230167050A (enExample) |
| AU (1) | AU2022254651A1 (enExample) |
| CA (1) | CA3214535A1 (enExample) |
| IL (1) | IL307393A (enExample) |
| MX (1) | MX2023011853A (enExample) |
| WO (1) | WO2022216645A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240208912A1 (en) * | 2021-03-11 | 2024-06-27 | Mirati Therapeutics, Inc. | MTA-Cooperative PRMT5 Inhibitors |
| EP4442680A4 (en) * | 2021-11-30 | 2026-05-06 | Abbisko Therapeutics Co Ltd | Pyrazole derivative, its preparation process and its use in medicine |
| EP4458812A1 (en) * | 2021-12-27 | 2024-11-06 | Medshine Discovery Inc. | Pyrazole-1(2h)-phthalazinone compound and application thereof |
| WO2024022186A1 (zh) * | 2022-07-29 | 2024-02-01 | 四川科伦博泰生物医药股份有限公司 | 甲基吡唑化合物、包含其的药物组合物及其制备方法和用途 |
| WO2024027703A1 (zh) * | 2022-08-02 | 2024-02-08 | 上海艾力斯医药科技股份有限公司 | 一种prmt5抑制剂、其制备方法及应用 |
| CN120265615A (zh) * | 2022-11-29 | 2025-07-04 | 正大天晴药业集团股份有限公司 | 含有二氢酞嗪的化合物 |
| WO2024177416A1 (ko) * | 2023-02-22 | 2024-08-29 | 단국대학교 천안캠퍼스 산학협력단 | Egfr 표적치료제 내성암 치료용 약학 조성물 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025157288A1 (zh) * | 2024-01-26 | 2025-07-31 | 上海湃隆生物科技有限公司 | 包含prmt5抑制剂和cdk4/6抑制剂的药物组合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016145150A2 (en) * | 2015-03-11 | 2016-09-15 | The Broad Institute Inc. | Selective treatment of prmt5 dependent cancer |
| JP2021176819A (ja) | 2018-07-31 | 2021-11-11 | アステラス製薬株式会社 | キナゾリン化合物を有効成分とする医薬組成物 |
| US11492351B2 (en) * | 2019-09-12 | 2022-11-08 | Mirati Therapeutics, Inc. | MTA-cooperative PRMT5 inhibitors |
| CR20220175A (es) * | 2019-10-22 | 2022-06-21 | Lupin Ltd | Combinación farmacéutica de inhibidores de PRMT5 |
-
2022
- 2022-04-05 EP EP22724161.9A patent/EP4319753A1/en active Pending
- 2022-04-05 CA CA3214535A patent/CA3214535A1/en active Pending
- 2022-04-05 AU AU2022254651A patent/AU2022254651A1/en active Pending
- 2022-04-05 WO PCT/US2022/023388 patent/WO2022216645A1/en not_active Ceased
- 2022-04-05 US US17/713,455 patent/US12171765B2/en active Active
- 2022-04-05 IL IL307393A patent/IL307393A/en unknown
- 2022-04-05 KR KR1020237035696A patent/KR20230167050A/ko active Pending
- 2022-04-05 JP JP2023561863A patent/JP2024513494A/ja active Pending
- 2022-04-05 MX MX2023011853A patent/MX2023011853A/es unknown
-
2024
- 2024-11-19 US US18/951,832 patent/US20250073241A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024513492A5 (enExample) | ||
| ES2456275T3 (es) | Derivados de quinazolina moduladores de la quinasa JAK y su uso en métodos | |
| CA2956628C (en) | Pyridinylaminopyrimidine derivatives, preparation process and use thereof | |
| CN103124729B (zh) | 作为Axl抑制剂的药物活性化合物 | |
| ES2989617T3 (es) | Moduladores de receptores de quimioquinas y usos de los mismos | |
| JP2021523159A5 (enExample) | ||
| JP2024502886A (ja) | がんを処置及び／又は予防するためのｓｏｓ１阻害薬の医薬組合せ | |
| JP7607841B1 (ja) | Ｐａｒｐ１阻害薬及びその使用 | |
| WO2023230477A1 (en) | Pyridine checkpoint kinase 1 (chk1) inhibitors and uses thereof | |
| HRP20230472T1 (hr) | Novi derivati hidroksikiseline, postupak njihove priprave i farmaceutski sastavi koji ih sadrže | |
| CN113316574A (zh) | Shp2抑制剂及其应用 | |
| JP2021522275A (ja) | サイクリン依存性キナーゼ阻害剤としての２−アミノ−ピリジンまたは２−アミノ−ピリミジン誘導体 | |
| BR112020020104A2 (pt) | inibidores heterobicíclicos de mat2a e métodos de uso para o tratamento de câncer | |
| CN112218850A (zh) | 整合应激通路的调节剂 | |
| TWI685498B (zh) | 新穎之巨環化合物，其製備方法及含彼之藥物組合物 | |
| KR20170049604A (ko) | Bub1 억제제로서의 벤질 치환된 인다졸 | |
| ES2585244T3 (es) | Composiciones y métodos para modular una cinasa | |
| WO2016179123A1 (en) | Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl) cyclopropanamine, its crystalline form and its salts | |
| TW201219383A (en) | Chemical compounds | |
| FR3008975A1 (fr) | Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| CA3161339A1 (en) | Cyclic compounds and methods of using same | |
| JP6554538B2 (ja) | 未分化リンパ腫キナーゼの多環状阻害剤 | |
| ES2682270T3 (es) | Combinación farmacéutica sinérgica para el tratamiento del carcinoma de células escamosas de cabeza y cuello | |
| JP2018532786A5 (enExample) | ||
| JP2014505662A5 (enExample) |